When was OncoSil Medical founded?

OncoSil Medical was founded in 2005 and raised its 1st funding round within a year of its incorporation.

Where is OncoSil Medical located?

OncoSil Medical is headquartered in Sydney, Australia.

How many employees does OncoSil Medical have?

As of Aug 31, 2026, the latest employee count at OncoSil Medical is 24.

Is OncoSil Medical a funded company?

OncoSil Medical is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on 2005.

When was the latest funding round of OncoSil Medical?

OncoSil Medical's latest funding was a $***** Post IPO round on May 26, 2025, with participation from 0 investor.

Where does OncoSil Medical rank among its competitors?

OncoSil Medical ranks 35th amongst 124 active competitors, of which 53 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Cue Biopharma, which secured $50M in Jul, 2026.

Who are the top competitors of OncoSil Medical?

OncoSil Medical's top competitors include Cue Biopharma, Arthrosi Therapeutics and Scholar Rock. Among them, Cue Biopharma secured the most recent funding round in July, 2026.

OncoSil Medical - 2026 Company Profile, Team, Funding & Competitors

OncoSil Medical is a public company based in Sydney (Australia), founded in 2005 by Martin Rogers. It operates as a Developer of a medical device for the treatment of pancreatic cancer. OncoSil Medical has raised an undisclosed amount in funding. The company has 124 active competitors, including 53 funded and 25 that have exited. Its top competitors include companies like Cue Biopharma, Arthrosi Therapeutics and Scholar Rock.

Company Details

Developer of a medical device for the treatment of pancreatic cancer. The company's flagship product includes OncoSil which is a brachytherapy device used for the treatment of pancreatic cancer. It is used to deliver beta radiation to the cancerous tissue by causing direct damage to the cancer cell DNA. The device contains proprietary diluent that acts as a carrier to implant the microparticles of radioisotope (phosphorous-32) to the targeted cell.

Website: www.oncosil.com/
Social
Email ID: *****@oncosil.com
Phone Number: +61 **********

Key Metrics

Founded Year

2005

Location

Sydney, Australia

Stage

Public

Latest Funding Round

Post IPO, May 26, 2025, $*****

Investors

Regal Funds Management

Ranked

35^th among 124 active competitors

Employee Count

24 as on Aug 31, 2026

Similar Companies

Cue Biopharma & 140 more

Exit Details

Public

View OncoSil Medical's full profile

OncoSil Medical got listed on Aug 15, 2005.

Click here to take a look at OncoSil Medical's IPO in detail

OncoSil Medical has raised funding over 4 rounds. Its first funding round was on 2005. OncoSil Medical has 1 institutional investor.

Here is the list of recent funding rounds of OncoSil Medical:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 26, 2025	9975608	Post IPO	7046763	5792366	3796699	5909853
Apr 29, 2022	9563946	Post IPO	4265284	8167922	1241686	8999642
Feb 17, 2016	1550336	Post IPO	8334223	7323442	3855285	Regal Funds Management

Access funding benchmarks and valuations. Sign up today!

View details of OncoSil Medical's funding rounds and investors

The founders of OncoSil Medical is Martin Rogers.

Here are the details of OncoSil Medical's key team members:

Martin Rogers: Co-Founder & Non-Executive Director of OncoSil Medical and founder of 1 other company.

View details of OncoSil Medical's Founder profiles and Board Members

OncoSil Medical's employee count trend

OncoSil Medical has 24 employees as of Aug 26. Here is OncoSil Medical's employee count trend over the years:

Employee count trend for OncoSil Medical

Uncover OncoSil Medical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoSil Medical include Cue Biopharma, Arthrosi Therapeutics and Scholar Rock. Here is the list of Top 10 competitors of OncoSil Medical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
2nd	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	61/100
3rd	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 10 others	61/100
4th	Acepodia 2017, Alameda (United States), Public	Developer of cancer immunotherapy to treat ovarian and breast cancer	$256M	Ridgeback Capital Management, 8VC & 10 others	59/100
5th	Thymmune 2019, Cambridge (United States), Seed	Developer of immunetherapeutics for immune-disorders	$7M	Pillar VC, NYBC Ventures & 6 others	59/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	58/100
7th	Interius Biotherapeutics 2020, Philadelphia (United States), Acquired	Developer of gene therapies for treating multiple diseases	$129M	Cormorant Asset Management, Fairmount Funds Management ... & 16 others	58/100
8th	Ouro Medicines 2024, San Francisco (United States), Acquired	Developer of therapeutics for people living with chronic immune-mediated diseases	$120M	New Enterprise Associates, TPG & 6 others	57/100
9th	D3 Bio 2018, Shanghai (China), Series B	Developer novel therapeutics for cancer	$370M	Sequoia Capital China, Temasek & 8 others	57/100
10th	GigaGen 2011, San Francisco (United States), Acquired	Developer of T-cell and antibody-based therapeutics	$36.1M	Claremont Creek Ventures, DOE & 5 others	57/100
35th	OncoSil Medical 2005, Sydney (Australia), Public	Developer of a medical device for the treatment of pancreatic cancer	-	Regal Funds Management	40/100